White Coat and Masked Hypertension in Chronic Kidney Disease: Importance of the Difference Between Office and Out-of-Office Blood Pressure Measurements

Gianfranco Parati, MD, FESC; Juan Eugenio Ochoa, MD, PhD; Grzegorz Bilo, MD, PhD

Combined use of office and out-of-office blood pressure (BP) measurements allows identification of a number of specific BP patterns, including conditions characterized by discrepant levels of office and out-of-office BP, the latter assessed through either home or 24h ambulatory BP monitoring. In untreated patients, these conditions are defined as white coat hypertension (WCH, elevated office and normal out-of-office BP), or masked hypertension (MH, normal office and elevated out-of-office BP), respectively. In treated patients, these conditions are defined as white coat uncontrolled hypertension (with uncontrolled office and normalized out-of-office BP), and masked uncontrolled hypertension (with normalized office and uncontrolled out-of-office BP in spite of treatment), respectively (Figure and Table). These different hypertension phenotypes are increasingly acknowledged to have clinical relevance, often leading to diagnostic failure and over- or undertreatment, respectively.\(^1,2\) The 2013 European Society of Hypertension/European Society of Cardiology Guidelines were the first to recommend considering treatment of MH,\(^3\) because of its clinical significance and the accumulated evidence showing the overall negative impact of MH on cardiovascular prognosis (close to that of sustained hypertension).\(^4–9\) The clinical relevance of WCH seems more controversial, with cross-sectional studies on the association between WCH and markers of organ damage yielding conflicting results. While some studies suggested that WCH is a “benign” condition, which should be identified only to avoid unnecessary antihypertensive treatment, other studies provided evidence of similar prevalence of organ damage in WCH as in sustained hypertension. Indeed, the incidence of cardiovascular events in subjects with WCH has been alternatively reported to be as low as in normotensive subjects, as high as in hypertensive patients, or intermediate between the 2 populations. However, the reproducibility of these findings, often based on a single ABPM and a single office BP measurement, is far from being optimal.\(^10\) Indeed, data provided by population-based studies, at variance from those reported in a number of small studies, support the view that WCH is not an entirely benign condition, and have consistently shown that subclinical organ damage (ie, increase in left ventricular mass index and in carotid intima-media thickness) is greater in WCH than in true normotensives.\(^11,12,13\) Moreover, the data provided by the PAMELA (Pressione Arteriosa Monitorate E Loro Associazioni) population have shown that WCH is associated with a number of metabolic and blood pressure–related risk factors that lead to an increased overall cardiovascular risk profile as compared with true normotensive subjects. They have also shown that WCH is associated with a much greater risk of developing conditions that further increase cardiovascular risk, such as diabetes mellitus, office and ambulatory hypertension, and left ventricular hypertrophy. Available evidence thus indicates that, although WCH is associated with a lower risk of cardiovascular morbidity and mortality than true hypertension, it carries an increased risk as compared with sustained normotension.\(^10\)

The recent 2017 US guidelines have made a major step forward in this field, by recommending that these different hypertension patterns should be identified among untreated and treated individuals, and that treatment decisions should be based on out-of-office BP (ambulatory or home),\(^14\) an indication further supported by the 2018 European Society of Cardiology/European Society of Hypertension Guidelines.\(^15\) These guidelines, in addition to promoting a larger use of out-of-office BP monitoring to manage these...
conditions, have recommended linking the decision to treat these patients to the assessment of individual levels of cardiovascular risk. The recommendation to focus on out-of-office BP appears to be of particular relevance in blacks, who are characterized by higher levels of office BP and prevalence of hypertension than whites. In these individuals, arterial hypertension starts earlier and is associated with higher cardiovascular risk, with a higher prevalence of nocturnal hypertension and nondipping BP pattern than in whites. Thus they represent a population of particular interest for investigating the clinical role of WCH and MH, as acknowledged by a consensus document published by the American Society of Hypertension and the American Society of Nephrology.

In this issue of the Journal of the American Heart Association (JAMA), Ku et al. offer additional information on the prevalence and prognostic relevance of WCH and MH-related phenomena in black patients with CKD. Their analysis included 610 participants of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study who had clinic BP and ambulatory BP measured in a relatively short time. The association of the absolute difference between clinic systolic BP (SBP) and awake or 24-hour SBP with death and end-stage renal disease was assessed. The authors found a U-shaped association of the clinic–ambulatory SBP difference with risk of death, but not with end-stage renal disease. A significant increase of both a positive and a negative office SBP–awake SBP difference was associated with a trend towards higher (adjusted) mortality risk as compared with patients with more similar office and ambulatory BP levels (adjusted hazard ratio 1.84; 95% CI 0.94–3.56). The increased risk of mortality associated with a larger difference between office and ambulatory BP characterized untreated/treated black patients with CKD when affected by BP patterns reflecting either WCH/white coat hypertension.

**Figure.** Definition of different blood pressure (BP) phenotypes, based on variable combination of office, ambulatory (A) or home BP levels in untreated subjects (A) and in treated hypertensive patients (B), respectively. Reprinted from Parati et al. with permission. Copyright ©2016, Wolters Kluwer Health, Inc. ABP indicates ambulatory blood pressure.
uncontrolled hypertension (identified by a positive office–ambulatory SBP difference) or MH/masked uncontrolled hypertension (identified by a negative office–ambulatory SBP difference). This association was still evident even after adjusting for office or ambulatory BP levels, thus supporting the clinical value of the office–ambulatory BP difference independently from a diagnosis of hypertension, based on office or out-of-office BP levels considered separately.

These results appear to be particularly important, given that in the CKD population, ≈10% to 30% of patients are reported to have WCH, and ≈30% to 60% of them have MH, thus strongly supporting use of out-of-office BP monitoring, in particular of 24-hour ABPM, in these patients. This study also supports previous evidence that not only MH carries a high risk of cardiovascular events, but also WCH cannot be regarded as an entirely innocent phenomenon, in particular in black CKD patients. The practical implications of these findings is that, even in the presence of WCH, patients with CKD who exhibit a large difference between office and ambulatory BPs may need close follow-up and intensive cardiovascular risk reduction, because this BP condition appears to be associated with an elevated mortality risk during long-term follow-up.

This study, in spite of the interesting points it presents, is not free from limitations, as acknowledged by the authors themselves. First, the authors have used the difference between office BP and 24-hour ABP as the primary predictor of outcome, rather than the difference between office BP and awake BP, given the known high prevalence of nighttime BP elevation in black subjects with CKD, which cannot be considered when focusing on daytime ABP levels only. Second, the terminology used in this article sometimes needs a proper interpretation, in particular when the authors refer to a positive or negative office–ABP difference by using the terms “white coat effect” or “masked effect,” respectively. There is indeed clear evidence that a difference between office and ABP levels reflects a more complex combination of factors, affecting both office BP and ABP levels, than just the emotional impact on office BP of a visit by a physician, which is responsible for the “true” white coat effect. Third, in this article, an isolated increase in the positive difference between office and ambulatory diastolic BP was not associated with death, whereas an isolated increase in the negative difference between office and ambulatory diastolic BP was. Such a discrepant behavior between systolic and diastolic BP when comparing office and out-of-office values is not adequately discussed in the article by Ku et al and might need further investigation.

Fourth, as acknowledged by the authors in their study limitations sessions, this study focused on data obtained in hypertensive black patients with CKD, which do not permit generalization of its results to all CKD patients with hypertension. Finally, only baseline ABPM data were considered, which may have introduced some inaccuracy in the estimates because of the limited reproducibility of a single ambulatory BP recording. In spite of these limitations, however, the study by Ku et al is able to clearly demonstrate that the magnitude of the difference between office and

### Table. Definition of White-Coat and Masked Hypertension Phenomena

| Phenomenon | Untreated individuals with elevated office BP ≥140/90 mm Hg and 24-h ABP <130/80 mm Hg and Awake ABP <135/85 mm Hg and Sleep ABP <120/70 mm Hg or Home BP <135/85 mm Hg |
| --- | --- |
| Masked hypertension | Untreated individuals with office BP <140/90 mm Hg and 24-h ABP ≥130/80 mm Hg and/or Awake ABP ≥135/85 mm Hg and/or Sleep ABP ≥120/70 mm Hg or Home BP ≥135/85 mm Hg |
| White-coat uncontrolled hypertension | Treated individuals with office BP <140/90 mm Hg and 24-h ABP ≥130/80 mm Hg and/or Awake ABP ≥135/85 mm Hg and/or Sleep ABP ≥120/70 mm Hg or Home BP ≥135/85 mm Hg |
| Masked uncontrolled hypertension | Treated individuals with office BP <140/90 mm Hg and 24-h ABP ≥130/80 mm Hg and/or Awake ABP ≥135/85 mm Hg and/or Sleep ABP ≥120/70 mm Hg or Home BP ≥135/85 mm Hg |

- Diagnoses require confirmation by repeating ambulatory or home BP monitoring within 3–6 months, depending on the individual’s total cardiovascular risk
- Ambulatory BP values obtained in the office during the first or last hour of a 24-h recording may also partly reflect the white-coat effect (“white-coat” window)
- Patients with office BP <140/90 mm Hg, 24-h BP <130/80 mm Hg, awake BP <135/85 mm Hg but sleep BP ≥120/70 mm Hg should be defined as having “Isolated Nocturnal Hypertension,” to be considered as a form of masked hypertension

ABP indicates ambulatory blood pressure; BP, blood pressure. Reprinted from Parati et al with permission. Copyright ©2014, Wolters Kluwer Health, Inc.
ambulatory SBP has prognostic relevance and should be assessed, at least in black hypertensive patients with CKD, on top of measuring average levels of office and ambulatory BP. It also emphasizes that both office and ambulatory BP are important and carry prognostically relevant complementary information.

These data provide additional support to what has been recently recommended by both US and European Guidelines, ie, the need to expand the use of out-of-office BP in daily practice. However, in order to more consistently support the clinical usefulness of ABPM and home BP monitoring in the routine assessment of CKD patients, as well as in a general population, we would need randomized intervention outcome trials aimed at comparing the impact on intermediate and hard end points of a hypertension management based on office or on out-of-office BP measurements, respectively. This would also allow identification of outcome-based thresholds for hypertension diagnosis and targets for treatment not only for office BP but also for out-of-office BP, a piece of information yet currently missing. It would also allow the design of treatment algorithms aimed at achieving these appropriately defined targets for each specific, office and out-of-office BP-based group, as well as exploration of their impact on clinical outcomes. The currently running MASTER (Masked-uncontrolled hypertension management based on office BP or on out-of-office [ambulatory] BP measurement) study (NCT02804074),22 focusing on patients with masked uncontrolled hypertension, is expected to provide information aimed at finally clarifying whether a management strategy based on out-of-office BP measurements might offer a greater benefit in terms of prevention or regression of organ damage and prevention of cardiovascular events than a management strategy based only on office BP readings.

The MASTER study might thus help assessing the actual value of out-of-office BP monitoring in improving cardiovascular protection. Until such data become available, it would nevertheless not seem sensible to completely disregard either subjects with MH having elevated home or ambulatory BP (daytime and/or nighttime), just because their BP in the office is not increased, or subjects with WCH or white coat uncontrolled hypertension, having office BP elevated, just because their out-of-office BP is not increased. These subjects certainly deserve careful follow-up over time and interventions focused on lifestyle changes. Whether they would also need pharmacological treatment has been critically addressed by both US and European hypertension guidelines,14,15 but the level of evidence supporting such recommendations is low (level C), and further investigations in the same line explored by the MASTER study are still needed.

Disclosures
None.

References
1. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilò G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Riuolpe LM, Shennan A, Staessen JA, van Montfrans G, Verdecchia P, Zanchetti A, Zang Y; European Society of Hypertension Working Group on Blood Pressure M. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–1768.
2. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilò G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Riuolpe LM, Shennan A, Staessen JA, van Montfrans G, Verdecchia P, Zanchetti A, Zang Y; European Society of Hypertension Working Group on Blood Pressure M and Cardiovascular V. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–1366.
3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaensen T, Cifkova R, De Backer G, Dominiczak A, Góraliers M, Grobbe DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Vliigima M, Waerbe H, Zannad F. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
4. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measuremen in elderly treated hypertensive patients. JAMA. 2004;291:1342–1349.
5. Hansen TW, Kikuya M, Thijis L, Bjorklund-Bodegard K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Jeppeesen J, Ibsen H, Imai Y, Staessen JA; Investigators I. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens. 2007;25:1554–1564.
6. Boggia J, Li Y, Thijis L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O’Brien E, Staessen JA. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219–1229.
7. Mancia G, Bombelli F, Facchetti R, Madotto F, Quarti-Trevano F, Polo Fiz H, Grassi G, Segà R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:225–232.
8. Booth JN III, Diaz KM, Seals SR, Ravenell J, Muntner P, Shimbo D. Masked hypertension and cardiovascular disease events in a prospective cohort of blacks: the Jackson Heart Study. Hypertension. 2016;68:501–510.
9. Stergiou GS, Asayama K, Thijis L, Kollia A, Niiranen TJ, Hozawa A, Bogia J, Johansson JK, Ohkubo T, Tsuji I, Jula AM, Imai Y, Staessen JA; International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014;63:675–682.
10. Mancia G, Grassi G, Parati G, Zanchetti A. White Coat Hypertension. An Unresolved Diagnostic and Therapeutic Problem, Pages 1–19. Springer International Publishing, Cham, Switzerland AG; 2015.
11. Sega R, Trocino G, Lanaroatti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385–1392.
12. Fukuhara M, Arima H, Ninomiya T, Hata J, Hirakawa Y, Doi Y, Yanemoto K, Mukai N, Nagata M, Ikeda F, Matsuruma K, Kitazono T, Kiyohara Y. White-coat and masked hypertension are associated with carotid atherosclerosis in a general population: the Hisayama study. Stroke. 2013;44:1512–1517.
13. Parati G, Ochoa JE, Bilò G, Agarwal R, Covic A, Dekker FW, Fliser D, Heine GH, Jager KA, Margani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Siscari R, Vanholder R, Wieck A, London G, Zoccali C; European Renal and Cardiovascular Medicine working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in chronic kidney disease part 3: out-of-office blood pressure monitoring: methods, thresholds, and patterns. Hypertension. 2016;67:1093–1101.
14. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Jones DW, Muntner P, Oviabieb B, Smith SC Jr, Spencer CC, Stafford RS, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACP/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association. Journal of the American Heart Association. 2018;7: e007841.
15. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Aboyans V, Desormais I; List of authors/Task Force members. 2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens.* 2018;36:2284–2309.

16. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez Cj, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation.* 2015;131:e29–e322.

17. Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am J Hypertens.* 2015;28:640–648.

18. Ravenell J, Shimbo D, Booth JN III, Sarpong DF, Ayemang C, Beatty Moody DL, Abdalla M, Spruill TM, Shallcross AJ, Bress AP, Muntner P, Ogbedegbe G. Thresholds for ambulatory blood pressure among African Americans in the Jackson Heart Study. *Circulation.* 2017;135:2470–2480.

19. Parati G, Ochoa JE, Bilò G, Agarwal R, Covic A, Dekker FW, Fiser D, Heine GH, Jager KJ, Gargani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Sicari R, Vanholder R, Wieck A, London G, Zoccali C; European Renal and Cardiovascular Medicine working group of the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA). Hypertension in chronic kidney disease part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. *Hypertension.* 2016;67:1102–1110.

20. Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. *J Am Soc Nephrol.* 2014;25:1630–1646.

21. Ku E, Hsu RK, Toot DS, Bae SR, Lipkowitz MS, Smogorzewski MJ, Grimes BA, Weir MR. Magnitude of the difference between clinic and ambulatory blood pressures and risk of adverse outcomes in patients with chronic kidney disease. *J Am Heart Assoc.* 2019;8:e011013. DOI: 10.1161/JAHA.118.011013.

22. Parati G, Agabiti-Rosei E, Bakris GL, Bilò G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelakovic B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsoufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A and Zhang Y. MASEd-unconTrolled hyperErtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. *BMJ Open.* 2018;8:e021038.

**Key Words:** Editorials • ambulatory blood pressure monitoring • end-stage renal disease • hypertension, kidney • mortality